Oxidative stress and neuroinflammation in alzheimer's disease and amyotrophic lateral sclerosis: From Biology to Therapeutic Strategies

Oxidative Stress and Neurodegenerative Disorders

Volumn , Issue , 2007, Pages 297-311

  Mhatre, Molina ^a,b   Hensley, Kenneth ^a,c  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80054034163     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-044452809-4/50155-1     Document Type: Chapter

References (115)

1. E Mrak and WS Griffin (2005) Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 26 349-354.
2. X Lin, G Koelsch, S Wu, D Downs, A Dashti and J Tang (2000) Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci USA 97 1456-1460.
3. J Walter, C Kaether, H Steiner and C Hass (2001) The cell biology of Alzheimer's disease: uncovering the secrets of secretases. Curr Opin Neurobiol 11 585-590.
4. H Akiyama, S Barger, S Barnum, B Bradt, J Bauer, GM Cole, NR Cooper, et al. (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21 383-421.
5. DJ Selkoe (2001) Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimer's Disease 3 75-80.
6. JA Hardy and GA Higgins (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256 184-185.
7. M Stalder, T Dellar, M Staufenbiel and M Jucker (2001) 3D-Reconstruction of microglia and amyloid in APP23 transgenic mice: no evidence of intracellular amyloid. Neurobiol Aging 22 427-434.
8. SD Yan, X Chen, J Fu, M Chen, H Zhu, A Rohar, T Slattery, L Zhao, M Nagashima, J Morser, A Migheli, P Nawroth, D Stern and AM Schmidt (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382 685-691.
9. K.J. El Khoury J, SE Hickman, CA Thomas, L Cao, SC Silverstein and JD Loike (1996) Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature 382 716-719.
10. DM Paresce, RN Ghosh and FR Maxfield (1996) Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron 17 553-565.
11. LF Lue, R Rydel, EF Brigham, LB Yang, H Hamper, GM Murphy Jr., L Brachova, SD Yan, DG Walker, Y Shen and J Rogers (2001) Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia 35 72-79.
12. Y Shen, L Lue, L Yang, A Roher, Y Kuo, R Strohmeyer, WJ Goux, V Lee, GV Johnson, SD Webster, NR Cooper, B Bradt and J Rogers (2001) Complement activation by neurofibrillary tangles in Alzheimer's disease. Neurosci Lett 305 165-168.
13. T Wyss-Coray and L Mucke (2002) Inflammation in neurodegenerative disease-a double-edged sword. Neuron 35 419-432.
14. SA Frautschy, F Yang, M Irrizarry, B Hyman, TC Saido, K Hsiao and GM Cole (1998) Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol 152 307-317.
15. WC Benzing, JR Wujek, EK Ward, D Shaffer, KH Ashe, SG Younkin and KR Brunden (1999) Evidence for glial-mediated inflammation in aged APP (SW) transgenic mice. Neurobiol Aging 20 581-589.
16. M Stalder, A Phinney, A Probst, B Sommer, M Staufenbiel and M Jucker (1999) Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol 154 1673-1684.
17. KD Bornemann, KH Wiederhold, C Pauli, F Ermini, M Stalder, L Schnell, B Sommer, M Jucker and M Staufenbiel (2001) Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am J Pathol 158 63-73.
18. K Susen and A Blochl (2005) Low concentrations of aggregated beta-amyloid induce neurite formation via the neurotrophin receptor p75. J Mol Med 83 720-735.
19. KC Suen, MS Yu, KF So, RC Chang and J Hugon (2003) Upstream signaling pathways leading to the activation of double-stranded RNA-dependent serine/threonine protein kinase in beta-amyloid peptide neurotoxicity. J Biol Chem 278 49819-49827.
20. R Williamson, T Scales, BR Clark, G Gibb, CH Reynolds, S Kellie, IN Bird, IM Varndell, PW Sheppard, I Everall and BH Anderton (2002) Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-beta peptide exposure: Involvement of Src f. J Neurosci 22 10-20.
21. RD Blitzer, T Wong, MG Giovannini, MN Pangalos, NK Robakis and EM Landau (2000) Amyloid beta peptides activate the phosphoinositide signaling pathway in oocytes expressing rat brain RNA. Brain Res Mol Brain Res 76 115-120.
22. EG McGeer and PL McGeer (2003) Inflammatory processes in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 27 741-749.
23. WF Stewart, C Kawas, M Corrada and EJ Metter (1997) Risk of Alzheimer's disease and duration of NSAID use. Neurology 48 626-633.
24. V.B.A. In t'Veld BA, A Ruitenberg, A Hoffman, LJ Launer, D.C.M. van Duijn CM, T Stijnen, MM Breteler and BH Stricker (2001) Nonsteroidal anti-inflammatory drugs and risk of Alzheimer's disease. N Engl J Med 345 1515-1521.
25. PL McGeer, M Schulzer and EG McGeer (1996) Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47 425-432.
26. JB Rich, DX Rasmusson, MF Folstein, KA Carson, C Kawas and J Brandt (1995) Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 45 51-55.
27. M Etminan, S Gill and A Samii (2003) Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 327 128-130.
28. PL McGeer, EG McGeer, J Rogers and J Sibley (1991) Anti-inflammatory drugs and Alzheimer's disease. Lancet 335 1037-1038.
29. IR Mackenzie and DG Munoz (1998) Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology 50 986-990.
30. GE Landreth and MT Heneka (2001) Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiol Aging 22 937-944.
31. I Tegeder, J Pfeilschifter and G Geisslinger (2001) Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 15 2057-2072.
32. S Weggen, JL Eriksen, P Das, SA Sagi, R Wang, CU Pietrzik, KA Findlay, TE Smith, MP Murphy, T Bulter, DE Kang, N Marquez-Sterling, TE Golde and EH Koo (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414 212-216.
33. GP Lim, T Chu, F Yang, W Beech, SA Frautschy and GM Cole (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21 8370-8377.
34. Q Yan, J Zhang, H Liu, S Babu-Khan, R Vassar, AL Biere, M Citron and G Landreth (2003) Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23 7504-7509.
35. T Van Groen and I Kadish (2005) Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology. Brain Res Brain Res Rev 48 370-378.
36. S Weggen, JL Eriksen, SA Sagi, CU Pietrzik, V Ozols, A Fauq, TE Golde and EH Koo (2003) Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J Biol Chem 278 31831-31837.
37. S Weggen, JL Eriksen, SA Sagi, CU Pietrzik, TE Golde and EH Koo (2003) Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling. J Biol Chem 278 30748-30754.
38. SA Sagi, S Weggen, JL Eriksen, TE Golde and EH Koo (2003) The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of B kinase, and. J Biol Chem 278 31825-31830.
39. JM Lehmann, JM Lenhard, BB Oliver, GM Ringold and SA Kliewer (1997) Peroxisome proliferator-activated recep-tors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272 3406-3410.
40. J Berger and DE Moller (2002) The mechanisms of action of PPARs. Ann Rev Med 53 350-409.
41. P Delerive, JC Fruchart and B Staels (2001) Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 169 453-459.
42. CK Combs, DE Johnson, JC Karlo, SB Cannady and GE Landreth (2000) Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 20 558-567.
43. MT Heneka, T Klockgether and DL Feinstein (2000) Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci 20 6862-6867.
44. MT Heneka, DL Feinstein, E Galea, M Gleichmann, U Wullner and T. Klock gether T (1999) Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducib. J Neuroimmunol 100 156-168.
45. SJ Baek, LC Wilson, CH Lee and TE Eling (2002) Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs) : inhibition of cyclooxygenase and induction of NSAID-activated gene. J Pharmacol Exp Ther 301 1126-1131.
46. F.F.G. De Felice FG and ST Ferreira (2002) Beta-amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease. Cell Mol Neurobiol 22 545-563.
47. T Thomas, TG Nadackal and K Thomas (2001) Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-beta aggregation. Neuroreport 12 3263-3267.
48. ED Agdeppa, V Kepe, A Petri, N Satyamurthy, J Liu, SC Huang, GW Small, GM Cole and JR Barrio (2003) In vitro detection of (S) -naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2. Neuroscience 117 723-730.
49. SZ Zhao, MW Reynolds, J Lejkowith, A Whelton and FM Arellano (2001) A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety. Clin Ther 23 1478-1491.
50. JL Eriksen, SA Sagi, TE Smith, S Weggen, P Das, DC McLendon, VV Ozols, KW Jessing, KH Zavitz, EH Koo and TE Golde (2003) NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 112 440-449.
51. NG Bazan, V Colangelo and WJ Lukiw (2002) Prostaglandins and other lipid mediators in Alzheimer's disease. Prostaglandins Other Lipid Mediat 26869 197-210.
52. CD Anfuso, G Assero, G Lupo, A Nicotra, G Cannavo, RP Strosznajder, P Rapisarda, R Pluta and M Alberghina (2004) Amyloid beta (1-42) and its beta (25-35) fragment induce activation and membrane translocation of cytosolic phospholipase A2 in bovine retina capillary pericy. Biochim Biophys Acta 1686 125-138.
53. Y Yao, CM Clark, JQ Trojanowski, VM Lee and D Pratico (2005) Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment. Ann Neurol 58 623-626.
54. H Manev, T Uz, K Sugaya and T Qu (2000) Putative role of neuronal 5-lipoxygenase in an aging brain. FASEB J 14 1464-1469.
55. T Uz, C Pesold, P Longone and H Manev (1998) Aging associated up-regulation of neuronal 5-lipoxygenase expression: putative role in neuronal vulnerability. FASEB J 12 439-449.
56. D Pratico, V Zhukareva, Y Yao, K Uryu, CD Funk, JA Lawson, JQ Trojanowski and VM Lee (2004) 12/15-lipoxygenase is increased in Alzheimer's disease: possible involvement in brain oxidative stress. Am J Pathol 164 1655-1662.
57. SA Frautschy, W Hu, P Kim, SA Miller, T Chu, ME Harris-White and GM Cole (2001) Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging 22 993-1005.
58. A Talvani, FS Machado, GC Santana, A Klein, L Barcelos, JS Silva and MM Teixeira (2002) Leukotriene B4 induces nitric oxide synthesis in Trypanosoma cruzi-infected murine macrophages and mediates resistance to infection. Infect Immunol 70 4247-4253.
59. XS Chen, JR Sheller, EN Johnson and CD Funk (1994) Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 372 179-182.
60. CD Funk (2001) Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science 294 1871-1875.
61. NR Madamanchi, RD Bukoski, MS Runge and GN Rao (1998) Arachidonic acid activates Jun N-terminal kinase in vascular smooth muscle cells. Oncogene 16 417-422.
62. MT Rizzo and C Carlo-Stella (1996) Arachidonic acid mediates interleukin-1 and tumor necrosis factor-alpha induced activation of the c-jun amino-terminal kinase in stromal cells. Blood 88 37792-37800.
63. CH Woo, YW Eom, MH Yoo, HJ You, HJ Han, WK Song, YJ Yoo, JS Chun and JH Kim (2000) Tumor necrosis factor alpha generates reactive oxygen species via a cytosolic phospholipase A2-linked cascade. J Biol Chem 275 32357-32362.
64. K Ono, K Hasegawa, Y Yoshiike, A Takashima, M Yamada and H Naiki (2002) Nordihydroguaiaretic acid potently breaks down pre-formed Alzheimer's beta-amyloid fibrils in vitro. J Neurochem 81 434-440.
65. K Ono, K Hasegawa, H Naiki and M Yamada (2004) Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res 75 742-750.
66. MS West, MC Mhatre, A Ceballos, S Ferrell, RA Floyd, SP Gabbita, B Gordon, P Grammas, L Hamdheydari, T Mai, S Mou, QN Pye, CA Stewart, S West, KS Williamson, F Zemlan and K Hensley (2004) The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits TNF? activation of microglia and extends survival of G93A-SOD1 transgenic mic. J Neurochem 91 133-143.
67. Mhatre M. Therapeutic role of 5-lipoxygenase inhibition in Alzheimer's disease. Drugs of the future, In Press
68. MC Mhatre, RA Floyd and K Hensley (2004) Oxidative stress and Neuroinflammation in Alzheimer's disease and amyotrophic lateral sclerosis: common links and potential therapeutic targets.. J Alzheimer's Dis. vn6 147-157.
69. DJ Selkoe (2000) The origins of Alzheimer disease: a is for amyloid. JAMA 283 1615-1617.
70. DJ Selkoe (2001) Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimer's Dis 3 75-80.
71. DJ Selkoe (2000) Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta. Ann NY Acad Sci 924 17-25.
72. RG Cutler, J Kelly, K Storie, WA Pedersen, A Tammara, K Hatanpaa, JC Troncoso and MP Mattson (2004) Involve-ment of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci USA 101 2070-2075.
73. PH Reddy and MF Beal (2005) Are mitochondria critical in the pathogenesis of Alzheimer's disease? Brain Res Brain Res Rev 49 618-632.
74. PH Reddy (2006) Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer's disease. J Neurochem 96 1-13.
75. K Hensley, JM Carney, MP Mattson, M Aksenova, M Harris, JF Wu, RA Floyd and DA Butterfield (1994) A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci USA 91 3270-3274.
76. C Behl, JB Davis, R Lesley and D Schubert (1994) Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77 817-827.
77. CS Casley, JM Land, MA Sharpe, JB Clark, MR Duchen and L Canevari (2002) Beta-amyloid fragment 25-35 causes mitochondrial dysfunction in primary cortical neurons. Neurobiol Dis 10 258-267.
78. CS Casley, L Canevari, JM Land, JB Clark and MA Sharpe (2002) Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J Neurochem 80 91-100.
79. MP Mattson (1995) Untangling the pathophysiochemistry of beta-amyloid. Nat Struct Biol 2 926-928.
80. ME McLellan, ST Kajdasz, BT Hyman and BJ Bacskai (2003) In vivo imaging of reactive oxygen species specifi-cally associated with thioflavine S-positive amyloid plaques by multiphoton microscopy. J Neurosci 23 2212-2217.
81. A Wong, HJ Luth, W Deuther-Conrad, S Dukic-Stefanovic, J Gasic-Milenkovic, T Arendt and G Munch (2001) Advanced glycation endproducts co-localize with inducible nitric oxide synthase in Alzheimer's disease. Brain Res 920 32-40.
82. Y Matsuoka, M Picciano, F.J. La Francois J and K Duff (2001) Fibrillar beta-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer's disease. Neuroscience 104 609-613.
83. KS Montine, PJ Kim, SJ Olson, WR Markesbery and TJ Montine (1997) 4-Hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease. J Neuropathol Exp Neurol 56 866-871.
84. LM Sayre, DA Zelasko, PL Harris, G Perry, RG Salomon and MA Smith (1997) 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 68 2092-2097.
85. PF Good, P Werner, A Hsu, CW Olanow and DP Perl (1996) Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol 149 21-28.
86. MA Smith, K Hirai, K Hsiao, MA Pappolla, PL Harris, SL Siedlak, M Tabaton and G Perry (1998) Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 70 2212-2215.
87. MA Pappolla, YJ Chyan, RA Omar, K Hsiao, G Perry, MA Smith and P Bozner (1998) Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for te. Am J Pathol 152 871-877.
88. I Kiprianova, S Schwab, J Fandrey and M Spranger (1997) Suppression of the oxidative burst in murine microglia by nitric oxide. Neurosci Lett 226 75-78.
89. CA Colton and DL Gilbert (1987) Production of superoxide anions by a CNS macrophage, the microglia. FEBS Lett 223 284-288.
90. KA Robinson, CA Stewart, QN Pye, X Nguyen, L Kenney, S Salzman, RA Floyd and K Hensley (1999) Redox-sensitive protein phosphatase activity regulates the phosphorylation state of p38 protein kinase in primary astrocyte culture. J Neurosci Res 55 724-732.
91. JH Su, G Deng and CW Cotman (1997) Neuronal DNA damage precedes tangle formation and is associated with up-regulation of nitrotyrosine in Alzheimer's disease brain. Brain Res 774 193-199.
92. J Haas, B Storch-Hagenlocher, A Biessmann and B Wildemann (2002) Inducible nitric oxide synthase and argini-nosuccinate synthetase: co-induction in brain tissue of patients with Alzheimer's dementia and following stimulatio. Neurosci Lett 322 121-125.
93. B.V. Del Bianca V, S Dusi, E Bianchini, P.E. Dal Pra E and F Rossi (1999) β Amyloid activates the O2 forming NADPH oxidase in microglia monocytes neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer's. J Biol Chem 274 15493-15499.
94. K Hensley, ML Maidt, Z Yu, H Sang, WR Markesbery and RA Floyd (1998) Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci 18 8126-8132.
95. X Huang, CS Atwood, MA Hartshorn, G Multhaup, LE Goldstein, RC Scarpa, MP Cuajungco, DN Gray, J Lim, RD Moir, RE Tanzi and AI Bush (1999) The Abeta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38 7609-7616.
96. SM Cardoso, S Santos, RH Swerdlow and CR Oliveira (2001) Functional mitochondria are required for amyloid beta-mediated neurotoxicity. FASEB J 15 1439-1441.
97. HS Kim, JH Lee, JP Lee, EM Kim, KA Chang, CH Park, SJ Jeong, MC Wittendorp, JH Seo, SH Choi and YH Suh (2002) Amyloid beta peptide induces cytochrome C release from isolated mitochondria. Neuroreport 13 1989-1993.
98. HK Anandatheerthavarada, G Biswas, MA Robin and NG Avadhani (2003) Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol 161 41-54.
99. A Nunomura, G Perry, MA Pappolla, RP Friedland, K Hirai, S Chiba and MA Smith (2000) Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J Neuropathol Exp Neurol 59 1011-1017.
100. D Pratico, K Uryu, S Leight, JQ Trojanoswki and VM Lee (2001) Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 21 4183-4187.
101. E Tamagno, P Bardini, A Obbili, A Vitali, R Borghi, D Zaccheo, MA Pronzato, O Danni, MA Smith, G Perry and M Tabaton (2002) Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis 10 279-288.
102. K Ayasolla, M Khan, AK Singh and I Singh (2004) Inflammatory mediator and beta-amyloid (25-35) -induced ceramide generation and iNOS expression are inhibited by vitamin E. Free Radic Biol Med 37 325-338.
103. V Conte, K Uryu, S Fujimoto, Y Yao, J Rokach, L Longhi, JQ Trojanowski, VM Lee, TK McIntosh and D Pratico (2004) Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. J Neurochem 90 758-764.
104. S Sung, Y Yao, K Uryu, H Yang, VM Lee, JQ Trojanowski and D Pratico (2004) Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J 18 323-325.
105. H Nakashima, T Ishihara, O Yokota, S Terada, JQ Trojanowski, VM Lee and S Kuroda (2004) Effects of alpha-tocopherol on an animal model of tauopathies. Free Radic Biol Med 37 176-186.
106. SY Park and DS Kim (2002) Discovery of natural products from Curcuma longa that protect cells from beta-amyloid insult: a drug discovery effort against Alzheimer's disease. J Nat Prod 65 1227-1231.
107. RW Stackman, F Eckenstein, B Frei, D Kulhanek, J Nowlin and JF Quinn (2003) Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Exp Neurol 184 510-520.
108. PP Zandi, JC Anthony, AS Khachaturian, SV Stone, D Gustafson, JT Tschanz, MC Norton, KA Welsh-Bohmer and JC Breitner (2004) Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements. Arch Neurol 61 82-88.
109. MC Morris, DA Evans, CC Tangney, JL Bienias, RS Wilson, NT Aggarwal and PA Scherr (2005) Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change. Am J Clin Nutr 81 508-514.
110. MC Morris, LA Beckett, PA Scherr, LE Hebert, DA Bennett, TS Field and DA Evans (1998) Vitamin E, and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Disord 12 121-126.
111. MC Morris, DA Evans, JL Bienias, CC Tangney and RS Wilson (2002) Vitamin E and cognitive decline in older persons. Arch Neurol 59 1125-1132.
112. M Sano, C Ernesto, RG Thomas, MR Klauber, K Schafer, M Grundman, P Woodbury, J Growdon, CW Cotman, E Pfeiffer, LS Schneider and LJ Thal (1997) A controlled trial of selegiline alpha-tocopherol or both as treatment for Alzheimer's disease. The Alzheimer's Disease. N Engl J Med 336 1216-1222.
113. CK Hand and GA Rouleau (2002) Familial amyotrophic lateral sclerosis. Muscle Nerve 25 135-159.
114. T Siddique and I Lalani (2002) Genetic aspects of amyotrophic lateral sclerosis. Adv Neurol 88 21-32.
115. K Hensley, RA Floyd, B Gordon, S Mou, QN Pye, CA Stewart, M West and KS Williamson (2002) Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J Neurochem 82 365-374.